When markets soar, fear sets in. But ditching a regular investing strategy at the top could sabotage long-term success.

Elston’s Bruce Williams discuss ResMed's results and margin momentum, and whether the stock still deserves a buy rating.

Not sure where to start this ASX FY25 reporting season? NAOS analyses keywords in earnings call transcripts to reveal the ...

Everyone hates the idea of losing money on shares, but can the fear hold you back from a lifetime of financial optimisation?